Effect of DPP-4 inhibitor on insulin therapy for patients with type 2 diabetes
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000006470
- Lead Sponsor
- Jikei University School of Medicine Kashiwa Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with type 1diabetes (fasting C-peptide less than 0.5mg/dL) 2)Patients with severe ketosis, diabetic coma or precoma within 6 months 3)Patients with severe infections, before or after operation, or serious trauma . 4)Patients with exceeding the moderate renal impairment (sCr: male>=1.5mg/dl, female>=1.3mg/dl). 5)Patients receiving GLP-1 analog 6)Patients receiving oral glucose lowering drug without metformin, SU or pioglitazone 7)Patients who are pregnant, breast-feeding and/or intention to become pregnant 8)Patients with allergy against sitagliptin 9)Other patients determined to be inappropriate by physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in responses of glucose, glucagon and C-peptide with sitagliptin treatment examined by OGTT
- Secondary Outcome Measures
Name Time Method Change of HbA1c, fasting plasma glucose, glucagon and C-peptide before and after sitagliptin treatment